>>you implying that SCTPF may have been able differentiate their drug enough so that they won't run into patent issues down the road (with Stanford or others)?
It's at least plausible that this approach might sidestep the very significant Stanford patent estate surrounding CD47. But it would be tough to make a stronger assertion than that without an awful lot of research.
Market Data 
Markets 
AI
